Herpes Simplex Therapeutics Market Size is expected to witness substantial growth at a significant CAGR by 2036, estimates DelveInsight

DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Herpes Simplex, historical and forecasted epidemiology, as well as the Herpes Simplex market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Herpes Simplex Market with DelveInsight's In-Depth Report @ Herpes Simplex Market Size- https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Herpes Simplex Market Report
• In April 2026, Assembly Biosciences announced that Phase Ib clinical data for its HSV helicase primase inhibitor candidates, ABI-5366 and ABI-1179, was presented at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, Germany.
• In April 2026, AiCuris announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to the New Drug Application (NDA) for pritelivir for the treatment of refractory HSV infection, with or without resistance, in immunocompromised patients. The NDA submission was supported by initial results from the pivotal Phase III clinical trial, in which pritelivir achieved its registrational primary endpoint. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in the fourth quarter of 2026.
• According to the World Health Organization, HSV-1 infection is highly prevalent globally, with a large proportion of the population acquiring the infection during childhood, often through non-sexual contact.
• Globally, HSV-2 remains a major cause of genital herpes, affecting hundreds of millions of individuals, with a higher burden observed in women compared to men.
• HSV infections are lifelong and characterized by periods of latency and reactivation, contributing to recurrent disease and sustained transmission within populations.
• A significant proportion of HSV infections remain asymptomatic or unrecognized, leading to underdiagnosis and continued spread of the virus.
• The incidence of HSV-2 infection remains substantial worldwide, particularly among sexually active populations, with younger adults at higher risk of acquisition.
• In the United States, epidemiological studies indicate a considerable burden of both HSV-1 and HSV-2 infections, with notable gender disparities and higher prevalence in females.
• Across the EU4 and the UK, the total gender-specific cases of herpes simplex showed a higher prevalence among females, accounting for approximately 55% of cases, compared to around 45% among males.
• The prevalence of recurrent herpes simplex cases in Japan showed HSV-2 accounted for over ~70%, with HSV-1 following at ~30%.
• The leading Herpes Simplex Companies such as Teva Pharmaceutical Industries Ltd., Sanofi, Carlsbad Tech, Novartis AG, Emcure Pharmaceuticals Ltd., Fresenius Kabi AG, Viatris, Inc., Apotex Inc., Glenmark Pharmaceuticals Inc., GSK plc and others.
• Promising Herpes Simplex Therapies such as Famciclovir, ASP2151, ASP2151, GSK208141, Zicam (Ionic zinc), Pritelivir, HDIT101, Valaciclovir, ME-609 and others.

Stay ahead in the Herpes Simplex Therapeutics Market with DelveInsight's Strategic Report @ Herpes Simplex Market Outlook- https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Herpes Simplex Epidemiology Segmentation in the 7MM
• Total Herpes Simplex Seroprevalence
• Total Herpes Simplex Symptomatic Cases
• Total Herpes Simplex Diagnosed Cases
• Herpes Simplex Gender-specific Diagnosed Cases
• Total Herpes Simplex Recurrent Cases

Download the report to understand which factors are driving Herpes Simplex epidemiology trends @ Herpes Simplex Prevalence- https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Herpes Simplex Approved Therapies
• Amenamevir (AMENALIEF): Maruho
Amenamevir (AMENALIEF), developed and commercialized by Maruho, is an oral helicase-primase inhibitor approved in Japan for the treatment of recurrent herpes simplex and herpes zoster. Unlike conventional nucleoside analog antivirals, AMENALIEF targets the herpesvirus helicase-primase complex, an essential enzyme for viral DNA replication, offering a novel mechanism of antiviral activity in HSV management.

Herpes Simplex Pipeline Analysis
• Pritelivir (AIC-316): AiCuris
Pritelivir (AIC-316) by AiCuris Anti-infective Cures AG is is an innovative, therapeutic candidate inhibiting HSV replication, currently being evaluated in a pivotal Phase III trial for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. In immunocompromised patients, HSV symptoms are more severe and include disseminated disease, keratitis, and encephalitis; resistances to marketed drugs are often described.

• ABI-5366: Assemblybio
ABI-5366, developed by Assemblybio , is a long-acting HSV helicase-primase inhibitor in Phase Ib development for recurrent genital herpes. The therapy targets the HSV helicase-primase complex, a validated antiviral mechanism, and has demonstrated reductions in viral shedding and genital lesion rates with potential for once-weekly oral dosing.

Get In-Depth Knowledge on Herpes Simplex Market Trends and Forecasts with DelveInsight @ Herpes Simplex Treatment Market- https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Herpes Simplex Drugs Market Insights
The uptake of therapies in the HSV market is expected to vary based on mechanism of action, clinical differentiation, dosing convenience, and target patient population of Herpes Simplex. Investigational helicase primase inhibitors such as pritelivir are projected to demonstrate relatively faster uptake, driven by their novel mechanism, activity against resistant HSV strains, and significant unmet need in immunocompromised patients with refractory infections. In addition, the potential for improved antiviral efficacy and reduced resistance compared with conventional nucleoside analogs may further support adoption following approval. In contrast, emerging pipeline candidates such as ABI-5366, ABI-1179, and Adibelivir (IM-250) are expected to follow a more gradual uptake trajectory as additional clinical efficacy, long-term safety, and dosing data become available. Their adoption is likely to be influenced by differentiation in antiviral durability, long-acting suppression potential, and positioning within recurrent HSV management.

Herpes Simplex Companies
Teva Pharmaceutical Industries Ltd., Sanofi, Carlsbad Tech, Novartis AG, Emcure Pharmaceuticals Ltd., Fresenius Kabi AG, Viatris, Inc., Apotex Inc., Glenmark Pharmaceuticals Inc., GSK plc and others.

Herpes Simplex Market Outlook
The HSV treatment market is evolving beyond the long-established use of nucleoside analog antivirals such as valacyclovir, and famciclovir, which have remained the standard of care for episodic and suppressive treatment for decades. Generic antivirals, particularly generic valacyclovir, acyclovir, and famciclovir, continue to account for a substantial share of the HSV treatment market due to their established efficacy, widespread availability, and lower treatment costs. The broad utilization of these low-cost generics has increased market competition and created pricing pressure for branded therapies, while maintaining nucleoside analog antivirals as the cornerstone of episodic and suppressive HSV management.

Herpes Simplex Treatment Market
Recent pipeline advancements have positioned helicase primase inhibition as a promising next-generation strategy in HSV treatment. Pritelivir (AiCuris), an investigational oral helicase-primase inhibitor, demonstrated positive Phase III results in refractory HSV infections in immunocompromised patients and has received FDA Priority Review, with a PDUFA target date in the fourth quarter of 2026. Additional candidates including ABI-5366, ABI-1179, and Adibelivir (IM-250) are also progressing through clinical development with the goal of improving antiviral potency, durability, and dosing convenience.

Unlock Strategic Insights with DelveInsight's Comprehensive Herpes Simplex Market Report @ Herpes Simplex Market Drivers and Barriers- https://www.delveinsight.com/sample-request/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Herpes Simplex Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Herpes Simplex Companies- Teva Pharmaceutical Industries Ltd., Sanofi, Carlsbad Tech, Novartis AG, Emcure Pharmaceuticals Ltd., Fresenius Kabi AG, Viatris, Inc., Apotex Inc., Glenmark Pharmaceuticals Inc., GSK plc and others.
• Herpes Simplex Therapies- Famciclovir, ASP2151, ASP2151, GSK208141, Zicam (Ionic zinc), Pritelivir, HDIT101, Valaciclovir, ME-609 and others.
• Herpes Simplex Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Herpes Simplex Unmet Needs, KOL's views, Analyst's views, Herpes Simplex Market Access and Reimbursement

Table of Content
1: Key Insights
2: Herpes Simplex Market Report Introduction
3: Herpes Simplex Market Overview at a Glance
4: Herpes Simplex Epidemiology and Market Methodology
5: Herpes Simplex Executive Summary
6: Key Events
7: Herpes Simplex Background and Overview
8: Herpes Simplex Epidemiology and Patient Population
9: Herpes Simplex Patient Journey
10: Herpes Simplex Marketed drugs
11: Herpes Simplex Emerging Drugs
12. Key Cross Competition
13: Herpes Simplex Unmet Needs
14: Herpes Simplex SWOT Analysis
15: Key Opinion Leaders' Views
16: Reimbursement and Market Access
17: Appendix
18: DelveInsight Capabilities
19: Disclaimer
20: About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.